Cara’s Korsuva Impresses Against Pruritus In Hemodialysis Patients
Pivotal KALM-2 Study Meets Primary Endpoint
Cara Therapeutics and licensee Vifor Pharma have released positive topline data from the KALM-2 study in chronic kidney disease patients with moderate-to-severe pruritus undergoing hemodialysis, using a first-in-class selective kappa opioid receptor agonist which does not enter the CNS.
